ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
Aims to increase compliance and improve outcomes for People with Diabetes (PwD)
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
The drug will be manufactured at the group's formulation facility at SEZ, Ahmedabad
Ranked 25th with an impressive growth rate of 29% among Indian pharma companies in FY 2021-22
In the UK, Bartec has been synonymous with Mediso products for 18 years, proof of a successful partnership
Evonik in association with Remondis has opened its first plant in India to ensure Zero Liquid Discharge. It is located at Dombivli in Western Maharashtra
With the introduction of this device, Alkem is entering the core inhalation therapeutics and envisaging that the drug will reach the lungs effectively in each inhalation with added patient awareness and adherence programmes
Subscribe To Our Newsletter & Stay Updated
